{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:16:59Z","timestamp":1764260219627,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1038\/s41375-021-01424-w","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T13:02:34Z","timestamp":1632574954000},"page":"476-481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients"],"prefix":"10.1038","volume":"36","author":[{"given":"Lisa","family":"Blixt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordana","family":"Bogdanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Buggert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Hober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemming","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kjellander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1848-910X","authenticated-orcid":false,"given":"Sara","family":"Mravinacova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Muschiol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4657-8532","authenticated-orcid":false,"given":"Peter","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4287-3179","authenticated-orcid":false,"given":"Marzia","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-3392","authenticated-orcid":false,"given":"C. I. Edvard","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Stromberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-4064","authenticated-orcid":false,"given":"Margaret","family":"S\u00e4llberg Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8327-846X","authenticated-orcid":false,"given":"Rula","family":"Zain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6614-5737","authenticated-orcid":false,"given":"Lotta","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-4865","authenticated-orcid":false,"given":"Anders","family":"\u00d6sterborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"key":"1424_CR1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1159\/000514071","volume":"144","author":"P Langerbeins","year":"2021","unstructured":"Langerbeins P, Eichhorst B. Immune dysfunction in patients with chronic lymphocytic leukemia and challenges during COVID-19 pandemic. Acta Haematol. 2021;144:508\u201318.","journal-title":"Acta Haematol"},{"key":"1424_CR2","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3324\/haematol.2016.151100","volume":"102","author":"M Palma","year":"2017","unstructured":"Palma M, Gentilcore G, Heimersson K, Mozaffari F, Nasman-Glaser B, Young E, et al. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica. 2017;102:562\u201372.","journal-title":"Haematologica"},{"key":"1424_CR3","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1097\/HS9.0000000000000564","volume":"5","author":"TA Mulder","year":"2021","unstructured":"Mulder TA, Pena-Perez L, Berglof A, Meinke S, Estupinan HY, Heimersson K, et al. Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia. Hemasphere. 2021;5:e564.","journal-title":"Hemasphere"},{"key":"1424_CR4","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/s41375-019-0481-1","volume":"0","author":"KA Rogers","year":"2019","unstructured":"Rogers KA, Mousa L, Zhao Q, Bhat SA, Byrd JC, El Boghdadly Z, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia. 2019;0:2527\u201330.","journal-title":"Leukemia"},{"key":"1424_CR5","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood.2020006965","volume":"136","author":"AR Mato","year":"2020","unstructured":"Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136:1134\u201343.","journal-title":"Blood"},{"key":"1424_CR6","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","volume":"34","author":"L Scarfo","year":"2020","unstructured":"Scarfo L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34:2354\u201363.","journal-title":"Leukemia"},{"key":"1424_CR7","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1182\/blood.2021011568","volume":"137","author":"Y Herishanu","year":"2021","unstructured":"Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165\u201373.","journal-title":"Blood"},{"key":"1424_CR8","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","volume":"35","author":"LE Roeker","year":"2021","unstructured":"Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021;35:2703\u20135.","journal-title":"Leukemia"},{"key":"1424_CR9","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41577-020-00471-1","volume":"20","author":"DS Khoury","year":"2020","unstructured":"Khoury DS, Wheatley AK, Ramuta MD, Reynaldi A, Cromer D, Subbarao K, et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat Rev Immunol. 2020;20:727\u201338.","journal-title":"Nat Rev Immunol"},{"key":"1424_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3109\/10428194.2015.1014363","volume":"56","author":"EAM Kimby","year":"2015","unstructured":"Kimby EAM, Mattsson M. First report from the Swedish CLL-registry: a nationwide registry with high coverage (Abstract XVI iwCLL Sydney). Leuk Lymphoma. 2015;56:42.","journal-title":"Leuk Lymphoma"},{"key":"1424_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","volume":"43","author":"PA Parmelee","year":"1995","unstructured":"Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995;43:130\u20137.","journal-title":"J Am Geriatr Soc"},{"key":"1424_CR12","doi-asserted-by":"publisher","first-page":"e03149-20","DOI":"10.1128\/JCM.03149-20","volume":"59","author":"V Higgins","year":"2021","unstructured":"Higgins V, Fabros A, Kulasingam V. Quantitative measurement of Anti-SARS-CoV-2 antibodies: analytical and clinical evaluation. J Clin Microbiol. 2021;59:e03149-20.","journal-title":"J Clin Microbiol"},{"key":"1424_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/infdis\/jiab256","volume":"224","author":"H Alkharaan","year":"2021","unstructured":"Alkharaan H, Bayati S, Hellstrom C, Aleman S, Olsson A, Lindahl K, et al. Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. J Infect Dis. 2021;224:407\u201314.","journal-title":"J Infect Dis"},{"key":"1424_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183:158\u2013168 e114.","journal-title":"Cell"},{"key":"1424_CR15","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","volume":"27","author":"EM Bange","year":"2021","unstructured":"Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021;27:1280\u20139.","journal-title":"Nat Med"},{"key":"1424_CR16","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881\u201392.","journal-title":"Blood"},{"key":"1424_CR17","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1038\/s41375-020-01030-2","volume":"34","author":"LE Roeker","year":"2020","unstructured":"Roeker LE, Knorr DA, Pessin MS, Ramanathan LV, Thompson MC, Leslie LA, et al. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia. 2020;34:3047\u20139.","journal-title":"Leukemia"},{"key":"1424_CR18","doi-asserted-by":"publisher","first-page":"100290","DOI":"10.1016\/j.xcrm.2021.100290","volume":"2","author":"SP Anand","year":"2021","unstructured":"Anand SP, Prevost J, Nayrac M, Beaudoin-Bussieres G, Benlarbi M, Gasser R, et al. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom onset. Cell Rep. Med. 2021;2:100290.","journal-title":"Cell Rep. Med"},{"key":"1424_CR19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41591-021-01296-8","volume":"27","author":"N Huang","year":"2021","unstructured":"Huang N, Perez P, Kato T, Mikami Y, Okuda K, Gilmore RC, et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med. 2021;27:892\u2013903.","journal-title":"Nat Med"},{"key":"1424_CR20","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s10875-021-01046-y","volume":"41","author":"H Kinoshita","year":"2021","unstructured":"Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, et al. Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency. J Clin Immunol. 2021;41:1146\u201353.","journal-title":"J Clin Immunol"},{"key":"1424_CR21","doi-asserted-by":"crossref","unstructured":"Gallagher KME, Leick MB, Larson RC, Berger TR, Katsis K, Yam JY, et al. SARS -CoV-2 T-cell immunity to variants of concern following vaccination. bioRxiv. 2021.","DOI":"10.1101\/2021.05.03.442455"},{"key":"1424_CR22","doi-asserted-by":"publisher","first-page":"eabf3698","DOI":"10.1126\/sciimmunol.abf3698","volume":"5","author":"CJ Reynolds","year":"2020","unstructured":"Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol. 2020;5:eabf3698.","journal-title":"Sci Immunol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01424-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01424-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T09:09:35Z","timestamp":1643706575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01424-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01424-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"17 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests. MB is a consultant for Oxford Immunotech.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}